Joshua Hexter Sells 137,000 Shares of Oramed Pharmaceuticals (NASDAQ:ORMP) Stock

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) COO Joshua Hexter sold 137,000 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $4.46, for a total transaction of $611,020.00. Following the transaction, the chief operating officer directly owned 1,023,384 shares in the company, valued at $4,564,292.64. This trade represents a 11.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Oramed Pharmaceuticals Stock Performance

Shares of ORMP opened at $4.60 on Friday. The company has a 50 day moving average price of $4.11 and a 200-day moving average price of $3.63. Oramed Pharmaceuticals Inc. has a fifty-two week low of $1.98 and a fifty-two week high of $5.19. The stock has a market capitalization of $188.28 million, a PE ratio of 1.78 and a beta of 1.21.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised Oramed Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, June 11th. One research analyst has rated the stock with a Hold rating, According to data from MarketBeat, the company currently has a consensus rating of “Hold”.

Institutional Investors Weigh In On Oramed Pharmaceuticals

Several institutional investors have recently bought and sold shares of ORMP. SB Capital Management Inc purchased a new stake in shares of Oramed Pharmaceuticals during the 4th quarter valued at $5,415,000. Marshall Wace LLP acquired a new position in Oramed Pharmaceuticals during the 4th quarter valued at about $738,000. Dimensional Fund Advisors LP increased its position in Oramed Pharmaceuticals by 5.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 158,209 shares of the biotechnology company’s stock valued at $538,000 after buying an additional 7,738 shares in the last quarter. Ritholtz Wealth Management purchased a new stake in Oramed Pharmaceuticals in the first quarter valued at about $529,000. Finally, Bank of America Corp DE raised its stake in Oramed Pharmaceuticals by 4.4% in the third quarter. Bank of America Corp DE now owns 149,667 shares of the biotechnology company’s stock valued at $395,000 after buying an additional 6,261 shares during the last quarter. 12.73% of the stock is currently owned by institutional investors and hedge funds.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.